BIIB · Biogen Inc. · Webcasts, Transcripts & Audio
$253.40
+2.92 (+1.17%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$37.46B
Shares
147.82M
Volume · Nov 13
1.03M
Avg daily vol (3M)
1.07M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Biogen Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Biogen Inc. (BIIB), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-17
Biogen Inc. (BIIB) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-10-28
Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript
Confident tone
Lupus development and commercialization
AMR and MBI market development
Growth product launches
Revenue
$2.80B
▲ 10.6% YoY Diluted EPS
$-0.14
▼ 104.4% YoY Gross margin
73.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Biogen Inc. (BIIB) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Biogen Inc. (BIIB) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-29
Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript
Confident tone
Late-stage registrational pipeline
BTK inhibitor (BIP-91) and competitive MS market
Appellu acquisition integration
Revenue
$2.74B
▲ 3.4% YoY Diluted EPS
$0.66
▼ 84.8% YoY Gross margin
71.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-07-14
Biogen Inc. (BIIB) July 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-07-12
Biogen Inc. (BIIB) July 12, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-07-07
Biogen Inc. (BIIB) July 7, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-13
Biogen Inc. (BIIB) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-29
Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript
Confident tone
Leqembi franchise and care pathway
Pellas/Pelagos acquisition
Growth product momentum
Revenue
$2.48B
▲ 1.9% YoY Diluted EPS
$2.15
▲ 31.1% YoY Gross margin
73.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-06
Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
Confident tone
Pipeline and R&D progress
Leqembi / Alzheimer's franchise
Newer product launches (Skyclaris, XERZUVEY, SPINRAZA HD)
Revenue
$2.28B*
▼ 7.1% YoY Gross margin
78.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-12
Biogen Inc. (BIIB) January 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-10-30
Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript
Confident tone
Launch product momentum
Late-stage pipeline and readouts
Tau / BIIB080 readout and external data read-throughs
Revenue
$2.53B
▲ 2.8% YoY Diluted EPS
$3.17
▲ 19.2% YoY Gross margin
73.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript
Confident tone
LEQEMBI / Alzheimer's franchise
Pipeline progress and milestones
Eisai partnership / Europe arbitration
Revenue
$2.65B
▲ 7.3% YoY Diluted EPS
$4.33
▲ 8.2% YoY Gross margin
77.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript
Positive tone
Pipeline and external innovation
LEQEMBI launch and growth
Alzheimer's prevention trials
Revenue
$2.43B
▲ 6.1% YoY Diluted EPS
$1.64
▼ 39.3% YoY Gross margin
74.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-12
Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript
Positive tone
LEQEMBI growth and Alzheimer's franchise
New product launches offsetting MS decline
Pipeline reprioritization and future readouts
Revenue
$2.45B*
▲ 2.9% YoY Gross margin
76.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Biogen Inc. (BIIB) Q3 2024 Earnings Call Transcript
Positive tone
ZURZUVAE launch
SKYCLARYS global expansion
LEQEMBI launch
Revenue
$2.47B
▼ 2.5% YoY Diluted EPS
$2.66
Gross margin
74.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Biogen Inc. (BIIB) Q2 2024 Earnings Call Transcript
Confident tone
LEQEMBI and Alzheimer's franchise
Business development and M&A (HI-Bio)
New product launches (SKYCLARYS, ZURZUVAE, Reata)
Revenue
$2.46B
▲ 0.4% YoY Diluted EPS
$4.00
▼ 1.7% YoY Gross margin
77.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-24
Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript
Positive tone
LEQEMBI launch and Alzheimer's market
Quarterly financial performance
SKYCLARYS launch and rare disease
Revenue
$2.29B
▼ 7% YoY Diluted EPS
$2.70
▲ 1.1% YoY Gross margin
76.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-13
Biogen Inc. (BIIB) Q4 2023 Earnings Call Transcript
Confident tone
LEQEMBI (Alzheimer's disease franchise)
SKYCLARYS launch and Friedreich's Ataxia
International expansion (Japan, Europe, Latin America)
Revenue
$2.39B*
▼ 6.2% YoY Gross margin
74.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Biogen Inc. (BIIB) Q3 2023 Earnings Call Transcript
Revenue
$2.53B
▲ 0.9% YoY Diluted EPS
$-0.47
▼ 106% YoY Gross margin
73.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-25
Biogen Inc. (BIIB) Q2 2023 Earnings Call Transcript
Revenue
$2.46B
▼ 5.1% YoY Diluted EPS
$4.07
▼ 43.8% YoY Gross margin
75.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-25
Biogen Inc. (BIIB) Q1 2023 Earnings Call Transcript
Revenue
$2.46B
▼ 2.7% YoY Diluted EPS
$2.67
▲ 29.6% YoY Gross margin
73.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-15
Biogen Inc. (BIIB) Q4 2022 Earnings Call Transcript
Revenue
$2.54B*
▼ 6.9% YoY Gross margin
77.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-25
Biogen Inc. (BIIB) Q3 2022 Earnings Call Transcript
Revenue
$2.51B
▼ 9.7% YoY Diluted EPS
$7.84
▲ 253.2% YoY Gross margin
81.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-20
Biogen Inc. (BIIB) Q2 2022 Earnings Call Transcript
Revenue
$2.59B
▼ 6.7% YoY Diluted EPS
$7.24
▲ 142.1% YoY Gross margin
81.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Biogen Inc. (BIIB) Q1 2022 Earnings Call Transcript
Revenue
$2.53B
▼ 6% YoY Diluted EPS
$2.06
▼ 23.4% YoY Gross margin
70.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-03
Biogen Inc. (BIIB) Q4 2021 Earnings Call Transcript
Revenue
$2.73B*
▼ 4.2% YoY Gross margin
75.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-20
Biogen Inc. (BIIB) Q3 2021 Earnings Call Transcript
Revenue
$2.78B
▼ 17.7% YoY Diluted EPS
$2.22
▼ 50.2% YoY Gross margin
81.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-22
Biogen Inc. (BIIB) Q2 2021 Earnings Call Transcript
Revenue
$2.77B
▼ 24.6% YoY Diluted EPS
$2.99
▼ 68.8% YoY Gross margin
83.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-22
Biogen Inc. (BIIB) Q1 2021 Earnings Call Transcript
Revenue
$2.69B
▼ 23.8% YoY Diluted EPS
$2.69
▼ 66.7% YoY Gross margin
82.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-03
Biogen Inc. (BIIB) Q4 2020 Earnings Call Transcript
Revenue
$2.85B
▼ 22.3% YoY Diluted EPS
$2.32
▼ 71.3% YoY Gross margin
82.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-21
Biogen Inc. (BIIB) Q3 2020 Earnings Call Transcript
Revenue
$3.38B
▼ 6.2% YoY Diluted EPS
$4.46
▼ 46.8% YoY Gross margin
86.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-22
Biogen Inc. (BIIB) Q2 2020 Earnings Call Transcript
Revenue
$3.68B
▲ 1.8% YoY Diluted EPS
$9.59
▲ 22.2% YoY Gross margin
88.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-22
Biogen Inc. (BIIB) Q1 2020 Earnings Call Transcript
Revenue
$3.53B
▲ 1.3% YoY Diluted EPS
$8.08
▲ 13% YoY Gross margin
87.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-30
Biogen Inc. (BIIB) Q4 2019 Earnings Call
Revenue
$3.67B
▲ 4.1% YoY Diluted EPS
$8.08
▲ 70.8% YoY Gross margin
87.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–36 of 36 webcasts
Key facts
CIK
875045
CUSIP
09062X103
13F (30d)
826 filings
761 filers
Visit website
Investor relations